Literature DB >> 21664945

Structural features discriminate androgen receptor N/C terminal and coactivator interactions.

Emily B Askew1, John T Minges, Andrew T Hnat, Elizabeth M Wilson.   

Abstract

Human androgen receptor (AR) transcriptional activity involves interdomain and coactivator interactions with the agonist-bound AR ligand binding domain (LBD). Structural determinants of the AR NH(2)- and carboxyl-terminal interaction between the AR NH(2)-terminal FXXLF motif and activation function 2 (AF2) in the LBD were shown previously by crystallography. In this report, we provide evidence for a region in AR LBD helix 12 outside the AF2 binding cleft that facilitates interactions with the FXXLF and LXXLL motifs. Mutagenesis of glutamine 902 to alanine in AR LBD helix 12 (Q902A) disrupted AR FXXLF motif binding to AF2, but enhanced coactivator LXXLL motif binding. Functional compensation for defective FXXLF motif binding by AR-Q902A was suggested by the slower dissociation rate of bound androgen. Functional importance of glutamine 902 was indicated by the charged residue germline mutation Q902R that caused partial androgen insensitivity, and a similar somatic mutation Q902K reported in prostate cancer, both of which increased the androgen dissociation rate and decreased AR transcriptional activity. High affinity equilibrium androgen binding was retained by alanine substitution mutations at Tyr-739 in AR LBD helix 5 or Lys-905 in helix 12 structurally adjacent to AF2, whereas transcriptional activity decreased and the androgen dissociation increased. Deleterious effects of these loss of function mutations were rescued by the helix stabilizing AR prostate cancer somatic mutation H874Y. Sequence NH(2)-terminal to the AR FXXLF motif contributed to the AR NH(2)- and carboxyl-terminal interaction based on greater AR-2-30 FXXLF motif peptide binding to the agonist-bound AR LBD than a shorter AR-20-30 FXXLF motif peptide. We conclude that helix 12 residues outside the AF2 binding cleft modulate AR transcriptional activity by providing flexibility to accommodate FXXLF or LXXLL motif binding.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664945      PMCID: PMC3199032          DOI: 10.1016/j.mce.2011.03.026

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  57 in total

1.  The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways.

Authors:  J J Voegel; M J Heine; M Tini; V Vivat; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

2.  Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling.

Authors:  Emily B Askew; Suxia Bai; Amanda J Blackwelder; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2010-05-06       Impact factor: 5.157

3.  Detection and modulation in vivo of helix-loop-helix protein-protein interactions.

Authors:  T Finkel; J Duc; E R Fearon; C V Dang; G F Tomaselli
Journal:  J Biol Chem       Date:  1993-01-05       Impact factor: 5.157

4.  Expression of recombinant androgen receptor in cultured mammalian cells.

Authors:  V E Quarmby; J A Kemppainen; M Sar; D B Lubahn; F S French; E M Wilson
Journal:  Mol Endocrinol       Date:  1990-09

5.  p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction.

Authors:  J L Shenk; C J Fisher; S Y Chen; X F Zhou; K Tillman; L Shemshedini
Journal:  J Biol Chem       Date:  2001-08-14       Impact factor: 5.157

6.  FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor.

Authors:  B He; J A Kemppainen; E M Wilson
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Functional analysis of a novel androgen receptor mutation, Q902K, in an individual with partial androgen insensitivity.

Authors:  Arzu Umar; Cor A Berrevoets; N Mai Van; Marije van Leeuwen; Michael Verbiest; Wim J Kleijer; Dennis Dooijes; J Anton Grootegoed; Stenvert L S Drop; Albert O Brinkmann
Journal:  J Clin Endocrinol Metab       Date:  2004-10-14       Impact factor: 5.958

8.  Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.

Authors:  Masaki Shiota; Akira Yokomizo; Yasuhiro Tada; Junichi Inokuchi; Katsunori Tatsugami; Kentaro Kuroiwa; Takeshi Uchiumi; Naohiro Fujimoto; Narihito Seki; Seiji Naito
Journal:  Mol Endocrinol       Date:  2009-11-02

9.  Structural and functional characterization of the interdomain interaction in the mineralocorticoid receptor.

Authors:  Jyotsna B Pippal; Yizhou Yao; Fraser M Rogerson; Peter J Fuller
Journal:  Mol Endocrinol       Date:  2009-06-18

10.  Human androgen receptor gene ligand-binding-domain mutations leading to disrupted interaction between the N- and C-terminal domains.

Authors:  J Jääskeläinen; A Deeb; J W Schwabe; N P Mongan; H Martin; I A Hughes
Journal:  J Mol Endocrinol       Date:  2006-04       Impact factor: 5.098

View more
  15 in total

1.  Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.

Authors:  Fiorella Magani; Stephanie O Peacock; Meghan A Rice; Maria J Martinez; Ann M Greene; Pablo S Magani; Rolando Lyles; Jonathan R Weitz; Kerry L Burnstein
Journal:  Mol Cancer Res       Date:  2017-08-15       Impact factor: 5.852

2.  Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules.

Authors:  Khalid Z Masoodi; Yadong Xu; Javid A Dar; Kurtis Eisermann; Laura E Pascal; Erica Parrinello; Junkui Ai; Paul A Johnston; Joel B Nelson; Peter Wipf; Zhou Wang
Journal:  Mol Cancer Ther       Date:  2017-06-27       Impact factor: 6.261

3.  N-terminal domain of the androgen receptor contains a region that can promote cytoplasmic localization.

Authors:  Javid A Dar; Kurtis Eisermann; Khalid Z Masoodi; Junkui Ai; Dan Wang; Tyler Severance; Sharanya D Sampath-Kumar; Zhou Wang
Journal:  J Steroid Biochem Mol Biol       Date:  2013-10-04       Impact factor: 4.292

4.  Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.

Authors:  Fayi Wu; Stephanie O Peacock; Shuyun Rao; Sandra K Lemmon; Kerry L Burnstein
Journal:  J Biol Chem       Date:  2012-12-31       Impact factor: 5.157

5.  Bisphenol A affects androgen receptor function via multiple mechanisms.

Authors:  Christina Teng; Bonnie Goodwin; Keith Shockley; Menghang Xia; Ruili Huang; John Norris; B Alex Merrick; Anton M Jetten; Christopher P Austin; Raymond R Tice
Journal:  Chem Biol Interact       Date:  2013-04-04       Impact factor: 5.192

6.  Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers.

Authors:  John T Minges; Shifeng Su; Gail Grossman; Amanda J Blackwelder; Elena A Pop; James L Mohler; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2012-11-21       Impact factor: 5.157

7.  Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.

Authors:  Mark A Titus; Brian Zeithaml; Boris Kantor; Xiangping Li; Karin Haack; Dominic T Moore; Elizabeth M Wilson; James L Mohler; Tal Kafri
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

Review 8.  Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.

Authors:  R Ferraldeschi; J Welti; J Luo; G Attard; J S de Bono
Journal:  Oncogene       Date:  2014-05-19       Impact factor: 9.867

9.  Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.

Authors:  Ji Ho Suh; Arundhati Chattopadhyay; Douglas H Sieglaff; Cheryl Storer Samaniego; Marc B Cox; Paul Webb
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

Review 10.  Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.

Authors:  Yu Zhao; Donald J Tindall; Haojie Huang
Journal:  Int J Biol Sci       Date:  2014-06-05       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.